Search Results - "Doronin, Vadim A"

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML by Adès, Lionel, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.

“…PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed…”
Get full text

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma by Moreau, Philippe, Karamanesht, Ievgenii I., Domnikova, Natalia, Kyselyova, Maryna Y., Vilchevska, Kateryna V., Doronin, Vadim A., Schmidt, Alexander, Hulin, Cyrille, Leleu, Xavier, Esseltine, Dixie-Lee, Venkatakrishnan, Karthik, Skee, Donna, Feng, Huaibao, Girgis, Suzette, Cakana, Andrew, van de Velde, Helgi, Deraedt, William, Facon, Thierry

“…Background and Objectives The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM) and, in the US, for the treatment of…”
Get full text

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma by Hulin, Cyrille, Richardson, Paul G., Attal, Michel, Goodman, Hugh J., Doronin, Vadim A, Spicka, Ivan, Le-Guennec, Solenn, Campana, Frank, van de Velde, Helgi, Beksac, Meral

“…In multiple myeloma (MM), deep responses have been associated with improvements in progression-free survival (PFS) and overall survival (OS). Response kinetic…”
Get full text

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954) by Sekeres, Mikkael A., Girshova, Larisa, Doronin, Vadim A, Diez-Campelo, Maria, Valcarcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Ciliao Munhoz, Eduardo, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Faller, Douglas V., Ades, Lionel

“…Background: Older patients with higher-risk MDS/CMML or AML with 20-30% marrow blasts typically receive single-agent hypomethylating agent (HMA) therapy…”
Get full text

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials by Vorobyev, Vladimir I., Zherebtsova, Vera A., Dubrovin, Egor I., Bychenkova, Liudmila A., Butaev, Lev S., Muha, Larisa A., Kochkareva, Yulia B., Ivanova, Valentina L., Nikitin, Eugene A., Tumyan, Gayane, Doronin, Vadim A, Krijanovski, Oleg I., Ptushkin, Vadim

“…Background. Ibrutinib became available for patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in Russia in the end of 2015 based on the…”
Get full text

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone by Sanchez, Larysa, Leleu, Xavier, Beaumont, Jennifer, Yu, Hailin, Hudgens, Stacie, Auner, Holger W, Quach, Hang, Delimpasi, Sosana, Spicka, Ivan, Pour, Luděk, Dimopoulos, Meletios A, Pylypenko, Halyna, Doronin, Vadim A, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Bahlis, Nizar J., Facon, Thierry, Chai, Yi, Ma, Xiwen, Tang, Shijie, Leong, Hoyee, Shah, Jatin J., Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

“…Introduction: The BOSTON study is a Phase 3 trial comparing the novel triplet regimen of once weekly oral selinexor with once weekly bortezomib and…”
Get full text

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study by Mateos, Maria, Jagannath, Sundar, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kryachok, Irina, Gavriatopoulou, Maria, Dimopoulos, Meletios A, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim A, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Moreau, Philippe, Levy, Moshe Y., Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

“…Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and…”
Get full text

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study by Richard, Shambavi, Chari, Ajai, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kryachok, Irina, Dimopoulos, Meletios A, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim A, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe Y., Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria-Victoria, Cavo, Michele, Chang, Hua, Landesman, Yosef, Joshi, Anita A., Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Grosicki, Sebastian, Richardson, Paul G.

“…Introduction: Despite recent advances, there remains an unmet need for novel therapies to improve outcomes and abrogate the adverse effects of high-risk…”
Get full text

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study by Mateos, Maria, Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W, Leleu, Xavier, Hajek, Roman, Dimopoulos, Meletios A, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kryachok, Irina, Pylypenko, Halyna, Doronin, Vadim A, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

“…Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and…”
Get full text

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study by Auner, Holger W, Gavriatopoulou, Maria, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Dimopoulos, Meletios A, Kryachok, Irina, Pylypenko, Halyna, Leleu, Xavier, Doronin, Vadim A, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe Y., Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria, Cavo, Michele, Joshi, Anita A., Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

“…Introduction: Treatment of older or frail patients (pts) with multiple myeloma (MM) remains challenging due to impaired organ function, underlying…”
Get full text

The Efficacy and Toxicity of Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Russian Multicenter Experience by Bondarenko, Sergey N., Maschan, Alexey A, Parovichnikova, Elena N., Shelekhova, Tatiana V, Doronin, Vadim A, Bogatyreva, Elena N, Kaplanov, Kamil D, Miakova, Natalia, Sokolov, Andrey N, Moiseev, Ivan S, Darskaya, Elena I, Samorodova, Irina V, Smirnova, Anna G, Paina, Olesya V, Bykova, Tatjana A, Ayubova, Bella I, Kulagin, Aleksandr D, Zubarovskaya, Ludmila S, Zander, Axel R, Afanasyev, Boris V

“…Introduction. The prognosis of patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), especially after allogeneic hematopoietic stem…”
Get full text

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics by Moreau, Philippe, Karamanesht, Ievgenii I, Domnikova, Natalia, Kyselyova, Maryna Y, Vilchevska, Kateryna, Doronin, Vadim A, Schmidt, Alexander, Hulin, Cyrille, Leleu, Xavier, Esseltine, Dixie-Lee, Venkatakrishnan, Karthik, Skee, Donna M, Feng, Huaibao, Girgis, Suzette, Cakana, Andrew Z, Deraedt, William M, Facon, Thierry

“…Abstract 1863 The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM); the recommended dose and schedule is 1.3 mg/m2…”
Get full text